Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Slideshows|January 24, 2022
Painful Diabetic Neuropathy Treatment: A Guideline Topline
Author(s)Steven A. King, MD, MS
Advertisement
Painful diabetic neuropathy (PDN) affects more than 16% of patients with diabetes and is the most common form of peripheral neuropathy.
The American Academy of Neurology recently issued a guideline on oral and topical treatments for PDN published in the journal
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
Most adolescents with sporadic colorectal cancer present with stage III or IV disease, and few have a family history, per data presented at AAP 2026.
Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood screening test.
Advertisement
Advertisement
Trending on Patient Care Online
1
Updated Freenome CRC Blood Test Detects 18.2% of Advanced Precancerous Lesions
2
Why Real-World Evidence Matters for Nonhormonal Menopause VMS Therapy
3
Most Adolescents With Colorectal Cancer Diagnosed at Advanced Stage, Study Finds
4
Real-World Nonhormonal Therapy Effects on VMS Bother, Work, and Mood
5